Drug Pipeline

Octreotide Acetate Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
1
Recruiting
3
Phase 3
4
Top Sponsors
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-06-03 NCT07623824 A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting… Phase 3 Not Yet Recruiting
Active Studies by Phase
Phase 3
3
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05477576 Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET… GEP-NET Recruiting
NCT00569127 Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients… Colorectal Neuroendocrine Tumor G1 Active, Not Recruiting
NCT07623824 A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting… Diagnosed With Acromegaly, Currently in the Active Stage of the Disease Not Yet Recruiting
Phase 1
NCT06558422 Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin Resistance Not Yet Recruiting
Sponsors Running Octreotide Acetate Trials
National Cancer Institute (NCI) (1) RayzeBio, Inc. (1) Columbia University (1) CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1)
Disease Areas
Obesity (1)
Get alerts when Octreotide Acetate trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free